Oramed Pharmaceuticals Inc. (ORMP)
Stock Price:
$2.60 USD
-0.19 (-6.81%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $2.50 -0.10 (-3.85%) Oct 21, 7:02 PM
Key Info
| Market Cap |
61.17M |
| Revenue (ttm) |
2.71M |
| Net Income (ttm) |
-10.80M |
| Shares Out |
23.53M |
| EPS (ttm) |
-0.57 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$2.60 |
| Previous Close |
$2.79 |
| Change ($) |
-0.19 |
| Change (%) |
-6.81% |
| Day's Open |
2.84 |
| Day's Range |
2.56 - 2.84 |
| Day's Volume |
68,414 |
| 52-Week Range |
2.32 - 6.05 |
More Stats
| Market Cap |
61.17M |
| Enterprise Value |
20.43M |
| Earnings Date (est) |
Jan 13, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
23.53M |
| Float |
19.32M |
| EPS (basic) |
-0.59 |
| EPS (diluted) |
-0.57 |
| FCF / Share |
-0.57 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
176,036 |
| Short Ratio |
0.79 |
| Short % of Float |
0.91% |
| Beta |
1.58 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
22.57 |
| PB Ratio |
1.85 |
| Revenue |
2.71M |
| Operating Income |
-11.09M |
| Net Income |
-10.80M |
| Free Cash Flow |
-13.25M |
| Net Cash |
40.74M |
| Net Cash / Share |
1.73 |
| Gross Margin |
96.42% |
| Operating Margin |
-409.04% |
| Profit Margin |
-398.30% |
| FCF Margin |
-489.08% |
| ROA |
-16.58% |
| ROE |
-38.78% |
| ROIC |
-40.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$9.67*
(271.92% upside)
Low
6.00
Current: $2.60
High
17.00
Target: 9.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 2.70 | 2.45 | 2.46 | 0.64 | - | - | - | - | - | - |
| Revenue Growth | 10.37% | -0.29% | 283.15% | - | - | - | - | - | - | - |
| Gross Profit | 2.61 | 2.54 | 2.27 | 0.15 | - | - | - | - | - | - |
| Operating Income | -14.63 | -13.53 | -10.77 | -10.01 | -7.38 | -5.91 | -4.30 | -2.88 | -2.44 | -2.97 |
| Net Income | -14.36 | -12.73 | -10.48 | -10.96 | -7.23 | -5.70 | -4.23 | -3.34 | -1.56 | -2.98 |
| Shares Outstanding | 17.45 | 14.88 | 13.31 | 12.62 | 10.82 | 9.24 | 7.21 | 5.88 | 5.42 | 4.78 |
| Earnings Per Share | -0.82 | -0.86 | -0.79 | -0.87 | -0.67 | -0.62 | -0.59 | -0.57 | -0.24 | -0.60 |
| Operating Cash Flow | -12.94 | -14.66 | -5.83 | 4.66 | -4.95 | -4.07 | -3.40 | -2.30 | -1.71 | -1.42 |
| Capital Expenditures | -0.02 | -0.01 | -0.01 | -0.01 | - | -0.01 | -0.01 | - | - | - |
| Free Cash Flow | -12.96 | -14.66 | -5.84 | 4.65 | -4.95 | -4.08 | -3.40 | -2.30 | -1.71 | -1.42 |
| Cash & Equivalents | 32.28 | 30.46 | 20.14 | 31.03 | 17.25 | 21.31 | 8.49 | 5.10 | 3.72 | 1.32 |
| Net Cash / Debt | 32.28 | 30.46 | 20.14 | 31.03 | 17.25 | 21.31 | 8.49 | 5.10 | 3.72 | 1.32 |
| Assets | 34.66 | 47.40 | 38.71 | 42.83 | 26.35 | 21.80 | 8.66 | 5.29 | 4.33 | 1.45 |
| Liabilities | 15.27 | 16.29 | 19.47 | 16.64 | 1.53 | 1.01 | 0.53 | 1.52 | 0.60 | 0.62 |
| Book Value | 19.39 | 31.11 | 19.24 | 26.19 | 24.83 | 20.79 | 8.13 | 3.78 | 3.72 | 0.83 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Oramed Pharmaceuticals Inc. |
| Country |
United States |
| CEO |
Nadav Kidron |
Stock Information
| Ticker Symbol |
ORMP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ORMP |
Description
Oramed Pharmaceuticals engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, which completed phase II clinical trials is an orally ingestible insulin capsule for the treatment of diabetes; and ORMD-0901 that completed phase I clinical trials is an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.